Aarvik Therapeutics Secures Strategic Investment from Laurus Labs in Series Seed 2 Financing Round
Aarvik Therapeutics, a pioneering biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, today announced a strategic investment by Laurus Labs, India, as part of its recently completed Series Seed 2 financing round. The investment underscores the growing confidence of global investors in Aarvik’s innovative approach to precision oncology and its potential to transform the therapeutic landscape for cancer patients.
Founded in 2021, Aarvik Therapeutics has rapidly established itself as a leader in the ADC field through the development of its proprietary MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform. Unlike conventional ADCs that are often limited to a narrow set of targets, the MUTTA™ platform is designed to broaden the applicability of ADCs across multiple cancer-associated antigens. By leveraging a multi-epitope targeting strategy, Aarvik aims to enhance the potency and specificity of ADCs, ultimately allowing for lower minimum effective doses (MED) while maintaining or increasing the maximum tolerated dose (MTD). This approach significantly improves the therapeutic window, which is critical in oncology treatments where balancing efficacy and safety is paramount.
The Series Seed 2 financing round attracted participation from a diverse group of investors, reflecting strong market confidence in Aarvik’s technology and its clinical development pipeline. Laurus Labs’ investment, in particular, represents a strategic partnership that combines Aarvik’s cutting-edge ADC research with Laurus’ expertise in pharmaceutical development and global manufacturing capabilities. The funding will enable Aarvik to accelerate the advancement of its ADC candidates, including those targeting hard-to-treat cancers, and to continue expanding its preclinical and early clinical programs.
Driving Innovation in ADC Therapeutics
ADCs are an emerging class of cancer therapeutics that couple the specificity of monoclonal antibodies with potent cytotoxic agents, delivering targeted treatment directly to tumor cells while minimizing systemic toxicity. While ADCs have shown substantial clinical success in certain cancer types, their broader application has been constrained by limitations in target selection, therapeutic window, and off-target toxicity. Aarvik’s MUTTA™ platform addresses these challenges by engineering tetravalent antibodies capable of engaging multiple epitopes on tumor cells simultaneously. This innovation enhances cellular uptake and cytotoxicity while potentially reducing the side effects commonly associated with high-dose ADC therapies.
“The investment by Laurus Labs is a strong endorsement of the progress we have made with our MUTTA™ platform,” said Jagath Reddy Junutula, PhD, Co-founder, President, and CEO of Aarvik Therapeutics. “Our mission has always been to deliver transformative benefits to patients facing hard-to-treat cancers. Partnering with world-class companies like Laurus Labs strengthens our ability to advance our pipeline and bring meaningful therapies to patients who need them most.”
Global Collaboration for Oncology Advancement
Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs, highlighted the company’s commitment to supporting breakthrough innovations in healthcare. “As part of our global strategy to invest in promising biotechnology ventures, we are delighted to support Aarvik Therapeutics in its efforts to develop next-generation oncology therapies,” Dr. Chava said. “We look forward to a productive collaboration that will drive forward innovative treatments and create tangible benefits for patients worldwide.”
The partnership between Aarvik Therapeutics and Laurus Labs exemplifies the growing trend of international collaboration in the biotech sector, where strategic investments not only provide financial support but also facilitate knowledge exchange, process optimization, and scalable manufacturing capabilities. This synergy is particularly critical in the development of complex biologics like ADCs, where precise engineering, robust preclinical validation, and scalable production are essential for successful clinical translation.
Advancing the Pipeline of Next-Generation ADCs
Since its inception, Aarvik Therapeutics has focused on building a robust pipeline of ADC candidates targeting cancers that have historically been difficult to treat. By combining its MUTTA™ platform with innovative linker and payload technologies, the company aims to maximize the therapeutic impact of its ADCs while minimizing toxicity. The Series Seed 2 funding will enable Aarvik to advance multiple programs simultaneously, including preclinical studies designed to optimize dosing regimens, evaluate safety profiles, and support future clinical trial initiation.
Beyond its technological innovation, Aarvik is committed to a patient-centric approach that prioritizes meaningful clinical outcomes. By expanding the therapeutic reach of ADCs, the company aims to address significant unmet needs in oncology, providing hope for patients with aggressive or treatment-resistant cancers.
The successful closing of the Series Seed 2 round marks a pivotal milestone in Aarvik Therapeutics’ growth trajectory. The infusion of capital, combined with strategic support from Laurus Labs, positions Aarvik to accelerate its research and development efforts, scale its operations, and strengthen its competitive position in the global oncology market.
“Aarvik is entering an exciting phase of growth,” said Dr. Junutula. “With the support of our investors, including Laurus Labs, we are well-positioned to advance our ADC programs and bring forward therapies that could redefine the standard of care for patients with challenging cancers. Our vision remains clear: to deliver next-generation targeted treatments that improve survival and quality of life for cancer patients worldwide.”
As the biotechnology sector continues to evolve, partnerships like that between Aarvik Therapeutics and Laurus Labs exemplify the potential of collaborative innovation to accelerate the development of life-saving therapies. With MUTTA™ at the forefront of its technology portfolio, Aarvik is set to make a meaningful impact in oncology, translating scientific discovery into clinical benefit for patients globally.
